Related references
Note: Only part of the references are listed.Pathophysiology of Gastroesophageal Reflux Disease
Guy E. Boeckxstaens et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2014)
Epidemiology of Gastroesophageal Reflux Disease
Joel H. Rubenstein et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2014)
Acid and Nonacid Reflux Monitoring
Dustin A. Carlson et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2014)
Efficacy of Tailored Helicobacter pylori Eradication Treatment Based on Clarithromycin Susceptibility and Maintenance of Acid Secretion
Mitsushige Sugimoto et al.
HELICOBACTER (2014)
The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin
E. A. Marcus et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Discovery, synthesis, and biological evaluation of novel pyrrole derivatives as highly selective potassium-competitive acid blockers
Haruyuki Nishida et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Discovery of a Novel Pyrrole Derivative 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Fumarate (TAK-438) as a Potassium-Competitive Acid Blocker (P-CAB)
Yasuyoshi Arikawa et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
High-Throughput Screening of Potassium-Competitive Acid Blockers
Mitsuyo Kondo et al.
JOURNAL OF BIOMOLECULAR SCREENING (2012)
An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers
G. Morelli et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands
Jun Matsukawa et al.
BIOCHEMICAL PHARMACOLOGY (2011)
A Study Comparing the Antisecretory Effect of TAK-438, a Novel Potassium-Competitive Acid Blocker, with Lansoprazole in Animals
Yasunobu Hori et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Characterization of a Novel Potassium-Competitive Acid Blocker of the Gastric H,K-ATPase, 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438)
Jai Moo Shin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
The effects of dose and timing of esomeprazole administration on 24-h, daytime and night-time acid inhibition in healthy volunteers
C. Wilder-Smith et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases
Yasunobu Hori et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Review article: strategies to determine whether hypergastrinaemia is due to Zollinger-Ellison syndrome rather than a more common benign cause
S. V. M. Murugesan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Review article: sleep-related gastro-oesophageal reflux as a distinct clinical entity
W. C. Orr
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
A Systematic Review of the Definitions, Prevalence, and Response to Treatment of Nocturnal Gastroesophageal Reflux Disease
Lauren B. Gerson et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Differences in Peptic Ulcer Between the East and the West
Rupert W. Leong
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2009)
Measurement of gastric pH in ambulatory esophageal pH monitoring
Shahin Ayazi et al.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES (2009)
Acid peptic diseases: pharmacological approach to treatment
Alex Mejia et al.
Expert Review of Clinical Pharmacology (2009)
A Randomized, Comparative Trial of a Potassium-Competitive Acid blocker (AZD0865)and Esomeprazole for the Treatment of Patients With Nonerosive Reflux Disease
John Dent et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Gastric mucosal defense and cytoprotection: Bench to bedside
Loren Laine et al.
GASTROENTEROLOGY (2008)
Control of gastric acid secretion in health and disease
Mitchell L. Schubert et al.
GASTROENTEROLOGY (2008)
Molecular mechanisms in therapy of acid-related diseases
J. M. Shin et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2008)
Chronic hypergastrinemia: Causes and consequences
Lori A. Orlando et al.
DIGESTIVE DISEASES AND SCIENCES (2007)
Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy
Mitsushige Sugimoto et al.
HELICOBACTER (2007)
The gastric H,K ATPase as a drug target - Past, present, and future
George Sachs et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2007)
Review article: acid-related disease - what are the unmet clinical needs?
P. O. Katz et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Pharmacogenetics of the proton pump inhibitors: A systematic review
E Chong et al.
PHARMACOTHERAPY (2003)
Review article:: the control of gastric acid and Helicobacter pylori eradication
G Sachs et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2000)
Differences in peptic ulcer between East and West
SK Lam
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2000)
Share Paper
